Expediting hit-to-lead progression in drug discovery through reaction prediction and multi-objective molecular optimization
The rapid and economical synthesis of novel bioactive compounds remains a significant hurdle in drug discovery efforts. This study demonstrates an integrated medicinal chemistry workflow that effectively diversifies hit and lead structures, enabling an efficient acceleration of the critical hit-to-l...
Saved in:
Published in | ChemRxiv |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , |
Format | Paper |
Language | English |
Edition | 2 |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The rapid and economical synthesis of novel bioactive compounds remains a significant hurdle in drug discovery efforts. This study demonstrates an integrated medicinal chemistry workflow that effectively diversifies hit and lead structures, enabling an efficient acceleration of the critical hit-to-lead optimization phase. Employing high-throughput experimentation (HTE), we generated a comprehensive data set encompassing 13,490 novel Minisci-type C-H alkylation reactions. This data set served as the foundation for training deep graph neural networks to accurately predict reaction outcomes. Scaffold-based enumeration of potential Minisci reaction products, starting from moderate inhibitors of monoacylglycerol lipase (MAGL), yielded a virtual library containing 26,375 molecules. This virtual chemical library was evaluated using reaction prediction, physicochemical property assessment, and structure-based scoring, identifying 212 potential MAGL inhibitor candidates. Of these, 14 ligands were synthesized and exhibited subnanomolar activity, representing a potency improvement of up to 4500 times over the original hit compound. These compounds also displayed favorable pharmacological profiles. Co-crystallization of three computationally designed ligands with the MAGL protein provided valuable structural insights into their preferred binding poses. This study demonstrates the potential of combining miniaturized HTE with deep learning and molecular property optimization to reduce cycle times in drug discovery. |
---|---|
AbstractList | The rapid and economical synthesis of novel bioactive compounds remains a significant hurdle in drug discovery efforts. This study demonstrates an integrated medicinal chemistry workflow that effectively diversifies hit and lead structures, enabling an efficient acceleration of the critical hit-to-lead optimization phase. Employing high-throughput experimentation (HTE), we generated a comprehensive data set encompassing 13,490 novel Minisci-type C-H alkylation reactions. This data set served as the foundation for training deep graph neural networks to accurately predict reaction outcomes. Scaffold-based enumeration of potential Minisci reaction products, starting from moderate inhibitors of monoacylglycerol lipase (MAGL), yielded a virtual library containing 26,375 molecules. This virtual chemical library was evaluated using reaction prediction, physicochemical property assessment, and structure-based scoring, identifying 212 potential MAGL inhibitor candidates. Of these, 14 ligands were synthesized and exhibited subnanomolar activity, representing a potency improvement of up to 4500 times over the original hit compound. These compounds also displayed favorable pharmacological profiles. Co-crystallization of three computationally designed ligands with the MAGL protein provided valuable structural insights into their preferred binding poses. This study demonstrates the potential of combining miniaturized HTE with deep learning and molecular property optimization to reduce cycle times in drug discovery. |
Author | Schneider, Gisbert Benz, Jörg Heer, Dominik Shema, Thierry Müller, Alex T. Binch, Hayley Hochstrasser, Remo Wittwer, Matthias B. van der Stelt, Mario Schneider, Petra Reutlinger, Michael Walter, Alexander Stenzhorn, Yannick Topp, Andreas Bürkler, Markus Kramer, Christian Haider, Achi Atz, Kenneth Grether, Uwe Martin, Rainer E. Nippa, David F. Tosstorff, Andreas Wolfard, Jens Kuhn, Bernd |
Author_xml | – sequence: 1 givenname: David F. orcidid: 0000-0002-0346-3786 surname: Nippa fullname: Nippa, David F. organization: Roche (Switzerland) – sequence: 2 givenname: Kenneth orcidid: 0000-0002-2628-1619 surname: Atz fullname: Atz, Kenneth organization: Roche (Switzerland) – sequence: 3 givenname: Yannick orcidid: 0009-0007-7444-3946 surname: Stenzhorn fullname: Stenzhorn, Yannick organization: Roche (Switzerland) – sequence: 4 givenname: Alex T. orcidid: 0000-0001-8063-9952 surname: Müller fullname: Müller, Alex T. organization: Roche (Switzerland) – sequence: 5 givenname: Andreas orcidid: 0000-0002-4969-3667 surname: Tosstorff fullname: Tosstorff, Andreas organization: Roche (Switzerland) – sequence: 6 givenname: Jörg surname: Benz fullname: Benz, Jörg organization: Roche (Switzerland) – sequence: 7 givenname: Hayley surname: Binch fullname: Binch, Hayley organization: Roche (Switzerland) – sequence: 8 givenname: Markus surname: Bürkler fullname: Bürkler, Markus organization: Roche (Switzerland) – sequence: 9 givenname: Achi orcidid: 0000-0002-5204-4473 surname: Haider fullname: Haider, Achi organization: Roche (Switzerland) – sequence: 10 givenname: Dominik orcidid: 0009-0003-2089-4339 surname: Heer fullname: Heer, Dominik organization: Roche (Switzerland) – sequence: 11 givenname: Remo surname: Hochstrasser fullname: Hochstrasser, Remo organization: Roche (Switzerland) – sequence: 12 givenname: Christian orcidid: 0000-0001-8663-5266 surname: Kramer fullname: Kramer, Christian organization: Roche (Switzerland) – sequence: 13 givenname: Michael orcidid: 0000-0001-9393-108X surname: Reutlinger fullname: Reutlinger, Michael organization: Roche (Switzerland) – sequence: 14 givenname: Petra surname: Schneider fullname: Schneider, Petra organization: ETH Zurich – sequence: 15 givenname: Thierry surname: Shema fullname: Shema, Thierry organization: Leiden University – sequence: 16 givenname: Andreas surname: Topp fullname: Topp, Andreas organization: Roche (Switzerland) – sequence: 17 givenname: Alexander surname: Walter fullname: Walter, Alexander organization: Roche (Switzerland) – sequence: 18 givenname: Matthias B. orcidid: 0000-0003-1359-4795 surname: Wittwer fullname: Wittwer, Matthias B. organization: Roche (Switzerland) – sequence: 19 givenname: Jens orcidid: 0000-0001-7338-4103 surname: Wolfard fullname: Wolfard, Jens organization: Roche (Switzerland) – sequence: 20 givenname: Bernd orcidid: 0000-0002-4301-562X surname: Kuhn fullname: Kuhn, Bernd organization: Roche (Switzerland) – sequence: 21 givenname: Mario surname: van der Stelt fullname: van der Stelt, Mario organization: Leiden University – sequence: 22 givenname: Rainer E. orcidid: 0000-0001-7895-497X surname: Martin fullname: Martin, Rainer E. organization: Roche (Switzerland) – sequence: 23 givenname: Uwe orcidid: 0000-0002-3164-9270 surname: Grether fullname: Grether, Uwe organization: Roche (Switzerland) – sequence: 24 givenname: Gisbert orcidid: 0000-0001-6706-1084 surname: Schneider fullname: Schneider, Gisbert organization: ETH Zurich |
BookMark | eNo1kMlOwzAYhC0EEqX0GfALGLwmzhFVbFIlLr1Xjv07cZXEkbPQwsvTqnCa0cynOcwduu5iBwg9MPrIMynkk62hTYcwE065IrQ51F9k5ldowVUuCOeFuEWrYdhTeuoZY1It0M_LoQcXxtBVuA4jGSNpwDjcp1glGIYQOxw67NJUYRcGG2dIRzzWKU5VjRMYO56RPp1GLtZ0DrdTMwYSyz2cshlwGxuwU2MSjv0Y2vBtzug9uvGmGWD1p0u0fX3Zrt_J5vPtY_28IbagnChwTFLneQle-FI4Lcosg1xrKKxQZWbBe8NKyF0BUubMO0u1KkTuKKjciyWil9n_f3Z9Cq1Jx12WF9oA15o5zhQzlEtVUKfEL0jra5g |
ContentType | Paper |
DBID | CQEMM |
DOI | 10.26434/chemrxiv-2025-0lxhw-v2 |
DatabaseName | ChemRxiv |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: CQEMM name: ChemRxiv url: https://chemrxiv.org/engage/chemrxiv/public-dashboard sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Chemistry |
EISSN | 2573-2293 |
Edition | 2 |
ExternalDocumentID | 6798ae2881d2151a024590d5 |
GroupedDBID | AFKRA ALMA_UNASSIGNED_HOLDINGS BENPR CCPQU CQEMM PHGZT PIMPY |
ID | FETCH-LOGICAL-c902-5ed140df2bef3fb3d83b66e788e9c35b6ceffa1be7d9e4471fdc085937d0e57f3 |
IEDL.DBID | CQEMM |
IngestDate | Fri Mar 14 12:02:40 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | English |
License | https://creativecommons.org/licenses/by/4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c902-5ed140df2bef3fb3d83b66e788e9c35b6ceffa1be7d9e4471fdc085937d0e57f3 |
Notes | G.S. and P.S. declare a potential financial conflict of interest as co-founders of inSili.com LLC, Zurich, and Xanadys LLC, Zurich. D.F.N., K.A., Y.S., A.T.M., A.T., J.B., H.B., M.B., A.H., D.H. R.H., C.K., M.R., T.S., A.T., A.W., M.B.W., J.W., B.K., R.E.M., and U.G. are full employees of F. Hoffmann-La Roche Ltd. |
ORCID | 0000-0002-3164-9270 0000-0002-4969-3667 0000-0001-8063-9952 0000-0002-0346-3786 0000-0002-5204-4473 0000-0001-8663-5266 0000-0002-4301-562X 0000-0001-7895-497X 0000-0001-9393-108X 0009-0007-7444-3946 0009-0003-2089-4339 0000-0001-6706-1084 0000-0003-1359-4795 0000-0002-2628-1619 0000-0001-7338-4103 |
OpenAccessLink | https://chemrxiv.org/engage/chemrxiv/article-details/6798ae2881d2151a024590d5 |
ParticipantIDs | chemrxiv_primary_6798ae2881d2151a024590d5 |
PublicationTitle | ChemRxiv |
SSID | ssj0002511145 |
Score | 1.2924032 |
SecondaryResourceType | preprint |
Snippet | The rapid and economical synthesis of novel bioactive compounds remains a significant hurdle in drug discovery efforts. This study demonstrates an integrated... |
SourceID | chemrxiv |
SourceType | Open Access Repository |
SubjectTerms | Artificial Intelligence Biological and Medicinal Chemistry Chemistry Chemoinformatics - Computational Chemistry Machine Learning Organic Chemistry Theoretical and Computational Chemistry |
Title | Expediting hit-to-lead progression in drug discovery through reaction prediction and multi-objective molecular optimization |
URI | https://chemrxiv.org/engage/chemrxiv/article-details/6798ae2881d2151a024590d5 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV07T8MwELZKOzDyFCBAHlgYrObhOMlctaqQgkAqUrfKji9tUJtUJS1F_HnOTlKxMLBFiWVFvvPd2ffdd4Q8cJAQC8VZBCplHGNwJlGXGKTcDVUcKmG5O5NnMX7jT9Ng2iFJWwuDf7ra7POdTeJDMcdNdXjXbxaT1ejKj77JIEjwIoy5jOeSJo0YOzo4Ij1UM867pDd4HSbJ4dLFxNMuD2qcF4YCPj9MjuriBcxZ7hefbGfvWJoPv9zN6IT0XuQaNqekA8UZOR60TdnOybehJta5wSrTRV6xqmRLlBK1MKuaYoPmBdWb7ZyaglsD0PyiTTMeigGiLWPA4SY_Yx9loalFFbJSvdfWj67anrm0RIuyako1L8hkNJwMxqzpn8DSGO1cABpPTzrzFGR-pnwd-UoIwDMvxKkfKJFClklXQahj4OikMp1a-rNQOxCEmX9JukVZwBWhqWH90q6jhOngJ6TkKsKtDjFXno_x-TV5bJdrtq5ZMmZ_CefmH2NvSbfabOEO_X6l7htp_gCVVLKr |
linkProvider | ChemRxiv |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV07b8IwELYoDIx9qq368NAOHSwgcV5DJwqC8lArUYkN2fEFqCBBvFH_Wn9cz3mgLh06sEWJFSXnz-c733d3hDxwEODZkjMXpM842uBMIJYY-LziSM-Rdly7s9O1Gx_8tW_1c-Q7y4XBL53Ot-N1HMSHcIiLan-vlAqTJezKRUlHEAQYLtpceucSOozolVXGsWzBboMe3OK5-YLT_WgY9Vqv2mBpkwHme6gMLFDoYqjAkBCYgTSVa0rbBnQMwfNNS9o-BIGoSHCUBxw1eaD8uEaYo8pgOYGJrz0iBUQ1d_OkUH2vdTr7Mx5tvle4ldDK0PIw-f5fEJ2GxcqT7WjD1vGRTvrg1-5WPyaFNzGD-QnJQXhKitWsB9wZ-dKVkNVYU6PpaLxky4hNEBQ0ZnUlFT3oOKRqvhpSnd-r-aA7mvb-oWiPxlkTOFyHg-JLESoakxhZJD8TZUunWYteGqECm6aZoeekdwhJXpB8GIVwSaivi4ypSlnaumGgLQSXLmoW8Lg0THQHrshTJq7BLCnKMfgLC9f_GHtPio1epz1oN7utG5JfzldwiybHUt6lM0vJ4MBY-gF7n_D_ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtZ3NT9swFMA9RiU4jgECxIYP7MDhLW3iJM2BU2kFY0VMYhLiUtnxCwTRJAppAe2f37ObZNUkDhy4RbIVRb882-_L7zF2KFBiFCgBfVQxCNLBQZIsAcaiF6ooVIGt3Tm-CE5_ix_X_vXKh5vmLgx96bR8Tuc2iI_ZLS0qRxZp42xqxx1SLbF6dPKyMFW2raPbNi9zTFhBotsnRcwcZ9LEFqOu9p2m05Rjaufr1GQVw11aQZXDA_EEmxC1KIYBaQa6nN2CuRprUilfoG6bA6TK2QsHNN1EUuwj2fxg8_8gV_eLfQqmTXdbyGntT-tLld8LndQZoOf48kT25ePx2QkJ4zfXHQ2vBqdQt0CAOKKtykdNBpBOXIWJlyhP9z0VBEhmK0ax56sgxiSRPYWhjlDQOZPo2FYwC3UX_TDx6LUfWYfWnCDDtDP4NRyPWw-UMS56wl8kvZFe5ImWLq0d14fuw_PdE8ytw6keWDp7R59Y51IWWG6wFcw-s_VB06Fuk_0Ztoj5EmK-hJinGTeIeYuY14h5g5j_Q8wJMf8PMW8R82XEW-zqPUhus9Usz3CH8diUQNO9rgpMO8NASqH6tO9hJJTrkbGyy44aXJNiUTJk8ppQ7r1h7gFbuzwZTX6eXZzvs9WqnOEX0ocq9bX-sZxN3lmU_gIGxS29 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Expediting+hit-to-lead+progression+in+drug+discovery+through+reaction+prediction+and+multi-objective+molecular+optimization&rft.jtitle=ChemRxiv&rft.au=Nippa%2C+David+F.&rft.au=Atz%2C+Kenneth&rft.au=Stenzhorn%2C+Yannick&rft.au=M%C3%BCller%2C+Alex+T.&rft.eissn=2573-2293&rft_id=info:doi/10.26434%2Fchemrxiv-2025-0lxhw-v2&rft.externalDocID=6798ae2881d2151a024590d5 |
thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fchemrxiv.org%2Fengage%2Fapi-gateway%2Fchemrxiv%2Fassets%2Forp%2Fresource%2Fitem%2F6798ae2881d2151a024590d5%2FsmallThumb%2Fexpediting-hit-to-lead-progression-in-drug-discovery-through-reaction-prediction-and-multi-objective-molecular-optimization.jpg |